The Developing Market for Alzheimer's Testing

The Developing Market for Alzheimer's Testing

As more drugs become available for treating Alzheimer's, so the need for more effective methods of diagnosis increases. How is this affecting the market for Alzheimer's testing?

Clinica Reports' latest title in the topical Industry Alert series charts new developments in both the treatment and diagnosis of Alzheimer's, and provides a companion volume to Scrip Reports' Alzheimer's Disease: Pathology and Treatment.

Rapid growth in the number of cases and the need for further research into the underlying causes of Alzheimer's are fuelling the need for new methods of diagnosis. Early diagnosis is key for the effective treatment of Alzheimer's, a disease which alone costs the US healthcare system $100 billion per year.

This report can help you to:

assess current methods of diagnosis and treatment
understand the latest technologies that are shaping the industry
anticipate the market and identify new business opportunities
compare new products
evaluate companies developing products that will affect the market before 2000.

Companies profiled include: Amersham; Athena; American Biogenetic Sciences; Nymox Pharmaceuticals; Eisai; and Warner-Lambert.

Price: £95/$200/¥23,000
Ref: CBS719E
Published: March 1997

For further information about this report, please contact our Customer Helpdesk on:
Tel: +44 (0)20 8332 8965 / 66
Fax: +44 (0)20 8332 8992
E-mail: [email protected]

Table of Contents

Introduction
What is Alzheimer's disease
Risk factors for Alzheimer's
Traditional diagnosis methods

The Alzheimer's disease market
The global picture
The US market
The Japanese market
The European market � major countries

Alzheimer's therapies
Acetycholinesterase inhibitors
Tacrine
Donepezil
Galatamine
Acetycholinesterase inhibitors in late stage development
Acetylcholine/receptor agonists in late-stage development
Muscarinic agonists

Alzheimer's tests
Biochemical markers
ADmark Assay (for beta amyloid and tau protein)
AD7C (neuronal thread protein)
INNOTEST hTAU (tau protein)
Diagnostic imaging
Ceretec
Neurolite
Genetic testing
ADmark Assay (ApoE-e4)/ADmark Profile (beta amyloid, tau and ApoE-e4)
INNO-LiPA ApoE (ApoE alleles)

Company profiles
Profiles of the five leading companies in Alzheimer's research